PT948518E - Molecula de acido nucleico isolada que codifica um antigenio associado ao cancro o proprio antigenio e suas utilizacoes - Google Patents

Molecula de acido nucleico isolada que codifica um antigenio associado ao cancro o proprio antigenio e suas utilizacoes

Info

Publication number
PT948518E
PT948518E PT97941626T PT97941626T PT948518E PT 948518 E PT948518 E PT 948518E PT 97941626 T PT97941626 T PT 97941626T PT 97941626 T PT97941626 T PT 97941626T PT 948518 E PT948518 E PT 948518E
Authority
PT
Portugal
Prior art keywords
nucleic acid
acid molecule
propriet
antigene
utilizations
Prior art date
Application number
PT97941626T
Other languages
English (en)
Portuguese (pt)
Inventor
Yao-Tseng Chen
Matthew Scanlan
Lloyd J Old
Elke Jager
Alexander Knuth
Jan W Drijfhout
Ali Gure
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Publication of PT948518E publication Critical patent/PT948518E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
PT97941626T 1996-10-03 1997-09-15 Molecula de acido nucleico isolada que codifica um antigenio associado ao cancro o proprio antigenio e suas utilizacoes PT948518E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/725,182 US5804381A (en) 1996-10-03 1996-10-03 Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof

Publications (1)

Publication Number Publication Date
PT948518E true PT948518E (pt) 2004-06-30

Family

ID=24913488

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97941626T PT948518E (pt) 1996-10-03 1997-09-15 Molecula de acido nucleico isolada que codifica um antigenio associado ao cancro o proprio antigenio e suas utilizacoes

Country Status (14)

Country Link
US (2) US5804381A (enExample)
EP (1) EP0948518B1 (enExample)
JP (1) JP3799483B2 (enExample)
KR (1) KR20000048851A (enExample)
CN (1) CN1283652C (enExample)
AT (1) ATE260930T1 (enExample)
AU (1) AU732068B2 (enExample)
CA (1) CA2266319C (enExample)
DE (1) DE69727966T2 (enExample)
DK (1) DK0948518T3 (enExample)
ES (1) ES2216169T3 (enExample)
NZ (1) NZ335485A (enExample)
PT (1) PT948518E (enExample)
WO (1) WO1998014464A1 (enExample)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6417165B1 (en) 1988-03-27 2002-07-09 Ludwig Institute For Cancer Research NY-ESO-1-peptide derivatives, and uses thereof
US6723832B1 (en) * 1996-10-03 2004-04-20 Ludwig Institute For Cancer Research Isolated peptides corresponding to amino acid sequences of NY-ESO-1, which bind to MHC Class I and MHC Class II molecules, and uses thereof
US6252052B1 (en) * 1996-10-03 2001-06-26 Cornell Research Foundation, Inc Antibodies which bind to NY-ESO-1 cancer associated proteins, and hybridomas which produce these antibodies
US6255470B1 (en) * 1996-10-03 2001-07-03 Memorial Sloan-Kettering Cancer Center Isolated nucleic acid molecule encoding an esophageal cancer associated antigen
US7888100B2 (en) * 1996-10-03 2011-02-15 Memorial Sloan-Kettering Cancer Research Isolated nucleic acid molecules which encode immunogenic portions of NY-ESO-1 protein
US6251603B1 (en) * 1996-10-03 2001-06-26 Ludwig Institute For Cancer Research Method for determining status of a cancerous condition by determining antibodies to NY-ESO-1 in a patient sample
US6794131B1 (en) * 1998-01-27 2004-09-21 Ludwig Institute For Cancer Research Lage-1 tumor associated nucleic acids
ZA98656B (en) 1997-01-27 1998-08-17 Ludwig Inst Cancer Res Lage-1 tumer associated nucleic acids
US6287756B1 (en) * 1997-05-05 2001-09-11 Ludwig Institute For Cancer Research Methods for determining presence of cancer in a sample by determining expression of an SSX gene
US6673350B2 (en) * 1997-05-05 2004-01-06 Ludwig Institute For Cancer Research Tumor associated peptide and uses thereof
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US6994851B1 (en) 1997-07-10 2006-02-07 Mannkind Corporation Method of inducing a CTL response
DE69837273T2 (de) * 1997-10-08 2008-01-31 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Menschliches krebsantigen ny eso-1/cag-3 und dazu kodierendes gen
US7084239B1 (en) 1997-10-08 2006-08-01 The United States Of America As Represented By The Department Of Health And Human Services Cancer peptides of NY-ESO-1/CAG-3
EP1806403A3 (en) * 1997-10-08 2008-01-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Human cancer antigen NY ESO 1/CAG-3 and gene encoding same
US7001999B1 (en) * 1998-04-15 2006-02-21 Ludwig Institute For Cancer Research Tumor associated nucleic acids and uses therefor
US6140050A (en) * 1998-06-26 2000-10-31 Ludwig Institute For Cancer Research Methods for determining breast cancer and melanoma by assaying for a plurality of antigens associated therewith
US6800730B1 (en) * 1998-10-02 2004-10-05 Ludwig Institute For Cancer Research Isolated peptides which bind to MHC class II molecules, and uses thereof
WO2000050595A2 (en) * 1999-02-25 2000-08-31 Ivan Gout Nucleic acid molecules associated with melanoma and thyroid tumors
DE19949595A1 (de) * 1999-10-14 2001-05-03 Deutsches Krebsforsch CTAGE-Genfamilie
CA2388301C (en) 1999-10-22 2011-01-04 Aventis Pasteur Limited Modified gp100 and uses thereof
US6689742B1 (en) * 2000-02-25 2004-02-10 Chancellors, Masters And Scholars Of The University Of Oxford NY-ESO-1 peptide derivatives, and uses thereof
WO2001068853A2 (en) * 2000-03-14 2001-09-20 The Johns Hopkins University School Of Medicine Immunogenic ovarian cancer genes
US6861234B1 (en) 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
EP1752160A3 (en) 2001-04-06 2007-05-30 Mannkind Corporation Epitope sequences
EP1390387A4 (en) * 2001-04-20 2004-12-08 Ludwig Inst Cancer Res TESTICLES CANCER ANTIGENS
US6794501B2 (en) * 2001-05-04 2004-09-21 Ludwig Institute For Cancer Research Colon cancer antigen panel
US7803382B2 (en) * 2001-05-04 2010-09-28 Ludwig Institute For Cancer Research Ltd. Method for inducing immune response to NY-CO-58
MXPA04005382A (es) 2001-11-07 2005-02-24 Mannkind Corp Vectores de expresion que codifican epitopes de antigenos asociados al objetivo y metodos para su diseno.
MY147019A (en) * 2002-03-13 2012-10-15 Biogen Idec Inc Anti-alpha v beta 6 antibodies
EP1545610A4 (en) * 2002-09-06 2006-11-08 Mannkind Corp EPITOPE SEQUENCES
US20080139464A1 (en) * 2003-05-30 2008-06-12 Ludwig Institute Of Cancer Research Isolated Ny-Eso-1 Peptides Which Bind To Hla Class II Molecules And Uses Thereof
US7178491B2 (en) * 2003-06-05 2007-02-20 Caterpillar Inc Control system and method for engine valve actuator
US20050118186A1 (en) * 2003-06-17 2005-06-02 Chih-Sheng Chiang Combinations of tumor-associated antigens in compositions for various types of cancers
WO2005033278A2 (en) * 2003-09-30 2005-04-14 Ludwig Institute For Cancer Research In vivo efficacy of ny-eso-1 plus iscom
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
WO2005114203A2 (en) * 2004-05-20 2005-12-01 The Regents Of The University Of California Dominant b cell epitopes and methods of making and using thereof
US20060008468A1 (en) * 2004-06-17 2006-01-12 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
US20060159689A1 (en) * 2004-06-17 2006-07-20 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
KR20070056042A (ko) * 2004-06-17 2007-05-31 맨카인드 코포레이션 에피토프 유사체
AU2005321898B2 (en) 2004-12-29 2012-07-19 Mannkind Corporation Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
WO2006071989A2 (en) * 2004-12-29 2006-07-06 Mannkind Corporation Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
NZ587601A (en) 2005-06-17 2012-05-25 Mannkind Corp Multivalent Entrain-and-Amplify Immunotherapeutics for Carcinoma
US7511118B2 (en) * 2005-06-17 2009-03-31 Mannkind Corporation PSMA peptide analogues
EP2385059A3 (en) 2005-06-17 2012-02-15 Mannkind Corporation Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
US8309096B2 (en) * 2007-01-15 2012-11-13 Glaxosmithkline Biologicals S.A. Fusion protein
WO2009046738A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
US8236318B2 (en) 2007-11-07 2012-08-07 Celldex Therapeutics Inc. Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
WO2009114207A2 (en) 2008-03-14 2009-09-17 Sanofi Pasteur Biologics Co. Replication-defective flavivirus vaccines and vaccine vectors
BRPI1009873A2 (pt) 2009-03-17 2016-03-08 Glaxosmithkline Biolog Sa detecção aperfeiçoada de expressão gênica
GB0910046D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
JP6002659B2 (ja) 2010-04-13 2016-10-05 セルデックス・セラピューティクス・インコーポレイテッド ヒトｃｄ２７に結合する抗体およびその使用
LT2714071T (lt) 2011-05-24 2019-10-10 Biontech Rna Pharmaceuticals Gmbh Individualizuotos vakcinos nuo vėžio
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
US8490054B2 (en) 2011-09-23 2013-07-16 The United States Of America As Represented By The Secretary Of The Army Software and related software tracking during software modification
NL2007536C2 (en) 2011-10-05 2013-04-08 Academisch Ziekenhuis Leiden Lumc Adjuvant compound.
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
WO2014074785A1 (en) 2012-11-08 2014-05-15 Ludwig Institute For Cancer Research Ltd. Methods of predicting outcome and treating breast cancer
AU2013351542B2 (en) 2012-11-28 2018-08-09 BioNTech SE Individualized vaccines for cancer
WO2014140938A2 (en) 2013-03-14 2014-09-18 Centre Hospitalier Universitaire Vaudois Immunological methods
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
PL3151921T3 (pl) 2014-06-06 2020-02-28 Bristol-Myers Squibb Company Przeciwciała przeciwko receptorowi indukowanego glukokortykoidami czynnika martwicy nowotworu (gitr) i ich zastosowania
EP3194970B1 (en) 2014-09-10 2021-07-28 F. Hoffmann-La Roche AG Immunogenic mutant peptide screening platform
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
WO2016145085A2 (en) 2015-03-09 2016-09-15 Celldex Therapeutics, Inc. Cd27 agonists
AU2016271111B2 (en) 2015-05-29 2022-04-28 Bristol-Myers Squibb Company Antibodies against OX40 and uses thereof
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
MX2018006072A (es) 2015-11-19 2018-08-01 Squibb Bristol Myers Co Anticuerpos contra receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos.
BR112018071307A2 (pt) 2016-04-18 2019-02-26 Celldex Therapeutics, Inc. anticorpos agonistas que ligam cd40 humana e usos dos mesmos
NL2018803B1 (en) 2017-04-27 2018-11-05 Academisch Ziekenhuis Leiden Handelend Onder De Naam Leids Univ Medisch Centrum/ H O D N Lumc Adjuvant compounds
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
AU2020402581A1 (en) 2019-12-11 2022-06-23 Molecular Partners Ag Designed ankyrin repeat domains with altered surface residues
KR20260071132A (ko) * 2024-11-11 2026-05-19 연세대학교 산학협력단 자폐증 개선 또는 치료를 위한 뇌내 조절 t 세포 활성화 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772547A (en) * 1986-02-03 1988-09-20 Hoffmann-La Roche Inc. HTLV-III envelope peptides
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5212085A (en) * 1987-12-09 1993-05-18 The General Hospital Corporation Sf-25 colon adenocarcinoma antigen, and antibodies with recognize this antigen
US5858689A (en) * 1993-07-22 1999-01-12 Ludwig Institute For Cancer Research Isolated peptides derived from the gage tumor rejection antigen precursor and uses thereof
US5709995A (en) * 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
US5830753A (en) * 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
DE69837273T2 (de) 1997-10-08 2008-01-31 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Menschliches krebsantigen ny eso-1/cag-3 und dazu kodierendes gen

Also Published As

Publication number Publication date
HK1020968A1 (en) 2000-05-26
EP0948518A4 (en) 2002-01-02
EP0948518A1 (en) 1999-10-13
JP2001507212A (ja) 2001-06-05
ATE260930T1 (de) 2004-03-15
CA2266319A1 (en) 1998-04-09
ES2216169T3 (es) 2004-10-16
CN1232467A (zh) 1999-10-20
EP0948518B1 (en) 2004-03-03
DE69727966D1 (de) 2004-04-08
CN1283652C (zh) 2006-11-08
WO1998014464A1 (en) 1998-04-09
KR20000048851A (ko) 2000-07-25
JP3799483B2 (ja) 2006-07-19
DE69727966T2 (de) 2005-02-10
US6274145B1 (en) 2001-08-14
DK0948518T3 (da) 2004-07-05
NZ335485A (en) 2001-01-26
AU4349597A (en) 1998-04-24
CA2266319C (en) 2005-12-20
US5804381A (en) 1998-09-08
AU732068B2 (en) 2001-04-12

Similar Documents

Publication Publication Date Title
DK0948518T3 (da) Isoleret nucleinsyremolekyle kodende for et cancer-associeret antigen, selve antigenet samt anvendelser deraf
PT690675E (pt) Acido nucleico que codifica um percursor de antigenio de rejeicao de tumor
DK0710253T3 (da) Antistoffer, der er specifikke mod human prostatakirtel-kallikrein
MX9603637A (es) Purificacion de anticuerpo.
ATE384119T1 (de) Isoprenoidproduktion
DK1129190T3 (da) Human TSLP DNA og polypeptider
HN1996000068A (es) Sistema de recubrimiento con vidrio de baja emisividad durable de alto funcionamiento, neutro unidades de vidrio aislante elaboradas a partir del mismo, y metodos para la fabricacion de los mismos.
AR006710A1 (es) Vidrio de sosa, nxido de calcio y silice
CR6538A (es) Anticuerpos de humano, anti-avb3 recombinantes, acidos nucleicos que codifican a los mismos y metodo de uso
PT752876E (pt) Anticorpos monoclonicos que se conectam com o percursor antigeneo de rejeicao de tumores mage-1, mage-1 recombinante, e peptidos imunogenicos derivados de mage-1
IL212140A0 (en) Antibodies against acpl polypeptides
DE69836823D1 (de) Jmy, mit-aktivator für p300/cbp, dafür kodierendenucleinsäure und deren verwendungen
DE69938240D1 (de) Neuer g-protein-gekoppelter rezeptor
ES2169779T3 (es) Procedimiento para la preparacion de poli(diorganosiloxanos), composiciones que contienen los mismos y su uso.
DK0724637T4 (da) Kortikotropinfrigørende faktor2-receptorer
ES2072868T3 (es) Proteina capaz de unir la fibronectina y su preparacion.
PT979235E (pt) Molecula de acido nucleico isolada que codifica os antigenios percusores de rejeicao ao tumor mage-c1 e mage-c2 e utilizacoes destes
EP0785716A4 (en) CYTOKIN DESCRIBED AS LERK6
DK0939769T3 (da) Vertebrat-Smoothened-proteiner
MX9102804A (es) Nuevas secuencias de acido nucleico que codifican enzimas sintasa de acido acetohidroxi.
ES2188545T3 (es) Polimeros que contienen aminoacidos basicos alcoxilados, concensados, y procedimiento para su obtencion.
ES2167106T3 (es) Procedimiento para preparar compuestos aromaticos que contienen grupos hidroxilo.
PT870015E (pt) Novas xilanases os genes que as codificam e as suas utilizacoes
ES2104130T3 (es) Adn hibrido, que codifica una subunidad de una toxina bacteriana con una hemolisina.
BR0116704A (pt) Antìgenos de streptococcus pyogenes e fragmentos de dna correspondentes